NCT03085056View on ClinicalTrials.gov

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Anaplastic Thyroid Cancer
Interventions
DRUG

Trametinib

trametinib orally 2mg daily during each 4 week cycle

DRUG

Paclitaxel

paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER